An antitumor cellular vaccine based on a mini-membrane IgE

Journal of Immunology

Volumn 188, Issue 1, 2012, Pages 103-110

  Nigro, Elisa A ^a,b,f   Soprana, Elisa ^b   Brini, Anna T ^a,c   Ambrosi, Alessandro ^d   Yenagi, Vijay A ^a   Dombrowicz, David ^e   Siccardi, Antonio G ^a,b   Vangelista, Luca ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e INSERM   (France)

^f SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CANCER ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOFLUOROMETRY; ENZYME RELEASE; FEMALE; GENETIC TRANSFECTION; IMMUNE SYSTEM; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; VACCINIA VIRUS; WESTERN BLOTTING;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; HUMANS; IMMUNOGLOBULIN E; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS; RECOMBINANT PROTEINS; VACCINATION; VACCINIA VIRUS;

EID: 84855406139     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101842     Document Type: Article

References (35)

1. Kinet, J. P. 1999. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu. Rev. Immunol. 17: 931-972.
2. Vangelista, L. 2003. Current progress in the understanding of IgE-FcepsilonRI interaction. Int. Arch. Allergy Immunol. 131: 222-233. (Pubitemid 36980755)
3. Gould, H. J., and B. J. Sutton. 2008. IgE in allergy and asthma today. Nat. Rev. Immunol. 8: 205-217. (Pubitemid 351323292)
4. Pate, M. B., J. K. Smith, D. S. Chi, and G. Krishnaswamy. 2010. Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective. Clin. Mol. Allergy 8: 3.
5. Altin, J., C. Shen, and A. Liston. 2010. Understanding the genetic regulation of IgE production. Blood Rev. 24: 163-169.
6. Jensen-Jarolim, E., G. Achatz, M. C. Turner, S. Karagiannis, F. Legrand, M. Capron, M. L. Penichet, J. A. Rodríguez, A. G. Siccardi, L. Vangelista, et al. 2008. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 63: 1255-1266.
7. Nigro, E. A., A. G. Siccardi, and L. Vangelista. 2010. IgE as adjuvant in tumor vaccination. In Cancer and IgE: Introducing the Concept of AllergoOncology, 1st Ed. M. L. Penichet, and E. Jensen-Jarolim, eds. Springer, New York. p. 215-229.
8. Fu, S. L., J. Pierre, T. A. Smith-Norowitz, M. Hagler, W. Bowne, M. R. Pincus, C. M. Mueller, M. E. Zenilman, and M. H. Bluth. 2008. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin. Exp. Immunol. 153: 401-409.
9. Reali, E., J. W. Greiner, A. Corti, H. J. Gould, F. Bottazzoli, G. Paganelli, J. Schlom, and A. G. Siccardi. 2001. IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res. 61: 5517-5522. (Pubitemid 32694936)
10. Nigro, E. A., A. T. Brini, E. Soprana, A. Ambrosi, D. Dombrowicz, A. G. Siccardi, and L. Vangelista. 2009. Antitumor IgE adjuvanticity: key role of Fc epsilon RI. J. Immunol. 183: 4530-4536.
11. Vangelista, L., E. Soprana, M. Cesco-Gaspere, P. Mandiola, G. Di Lullo, R. N. Fucci, F. Codazzi, A. Palini, G. Paganelli, O. R. Burrone, and A. G. Siccardi. 2005. Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner. J. Immunol. 174: 5602-5611. (Pubitemid 40593201)
12. Di Lullo, G., E. Soprana, M. Panigada, A. Palini, V. Erfle, C. Staib, G. Sutter, and A. G. Siccardi. 2009. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. J. Virol. Methods 156: 37-43.
13. Di Lullo, G., E. Soprana, M. Panigada, A. Palini, A. Agresti, C. Comunian, A. Milani, I. Capua, V. Erfle, and A. G. Siccardi. 2010. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. J. Virol. Methods 163: 195-204.
14. Dombrowicz, D., A. T. Brini, V. Flamand, E. Hicks, J. N. Snouwaert, J. P. Kinet, and B. H. Koller. 1996. Anaphylaxis mediated through a humanized high affinity IgE receptor. J. Immunol. 157: 1645-1651. (Pubitemid 126449106)
15. Dombrowicz, D., V. Flamand, K. K. Brigman, B. H. Koller, and J. P. Kinet. 1993. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell 75: 969-976. (Pubitemid 24014553)
16. Wiegand, T. W., P. B. Williams, S. C. Dreskin, M. H. Jouvin, J. P. Kinet, and D. Tasset. 1996. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J. Immunol. 157: 221-230.
17. Gilbert, P. A., L. Comanita, J. Barrett, A. Peters, M. Szabat, G. McFadden, and G. A. Dekaban. 2005. Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: implication for vaccine development. Cytotechnology 48: 79-88. (Pubitemid 41752628)
18. Staib, C., I. Drexler, M. Ohlmann, S. Wintersperger, V. Erfle, and G. Sutter. 2000. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28: 1137-1142, 1144-1146, 1148.
19. Li, E., A. Pedraza, M. Bestagno, S. Mancardi, R. Sanchez, and O. Burrone. 1997. Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng. 10: 731-736. (Pubitemid 27332082)
20. Gasparri, A., M. Moro, F. Curnis, A. Sacchi, S. Pagano, F. Veglia, G. Casorati, A. G. Siccardi, P. Dellabona, and A. Corti. 1999. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res. 59: 2917-2923. (Pubitemid 29283132)
21. Pinheiro, J. C., and D. M. Bates. 2000. Mixed-effects models in S and S-PLUS. In Statistics and Computing Series. J. Chambers, D. J. Hand, and W. K. Härdle, eds. Springer-Verlag, New York.
22. Yang, L., N. Yamagata, R. Yadav, S. Brandon, R. L. Courtney, J. D. Morrow, Y. Shyr, M. Boothby, S. Joyce, D. P. Carbone, and R. M. Breyer. 2003. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111: 727-735. (Pubitemid 36278591)
23. Sun, S., C. T. Ting, and C. I. Wu. 2004. The normal function of a speciation gene, Odysseus, and its hybrid sterility effect. Science 305: 81-83. (Pubitemid 38869375)
24. Goddard, M. R., H. C. Godfray, and A. Burt. 2005. Sex increases the efficacy of natural selection in experimental yeast populations. Nature 434: 636-640. (Pubitemid 40488554)
25. Howard, R. J., E. Juszczak, C. G. Ballard, P. Bentham, R. G. Brown, R. Bullock, A. S. Burns, C. Holmes, R. Jacoby, T. Johnson, et al CALM-AD Trial Group. 2007. Donepezil for the treatment of agitation in Alzheimer's disease. N. Engl. J. Med. 357: 1382-1392. (Pubitemid 47535593)
26. Skvara, H., M. Dawid, E. Kleyn, B. Wolff, J. G. Meingassner, H. Knight, T. Dumortier, T. Kopp, N. Fallahi, G. Stary, et al. 2008. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest. 118: 3151-3159.
27. Bestagno, M., L. Vangelista, P. A. Mandiola, S. Mukherjee, J. Sepúlveda, and O. R. Burrone. 2001. Membrane immunoglobulins are stabilized by interchain disulfide bonds occurring within the extracellular membrane-proximal domain. Biochemistry 40: 10686-10692. (Pubitemid 32816682)
28. Wurzburg, B. A., S. C. Garman, and T. S. Jardetzky. 2000. Structure of the human IgE-Fc C epsilon 3-C epsilon 4 reveals conformational flexibility in the antibody effector domains. Immunity 13: 375-385.
29. Wan, T., R. L. Beavil, S. M. Fabiane, A. J. Beavil, M. K. Sohi, M. Keown, R. J. Young, A. J. Henry, R. J. Owens, H. J. Gould, and B. J. Sutton. 2002. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat. Immunol. 3: 681-686. (Pubitemid 34752478)
30. Holdom, M. D., A. M. Davies, J. E. Nettleship, S. C. Bagby, B. Dhaliwal, E. Girardi, J. Hunt, H. J. Gould, A. J. Beavil, J. M. McDonnell, et al. 2011. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI. Nat. Struct. Mol. Biol. 18: 571-576.
31. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-1038.
32. Acres, B., and J. Y. Bonnefoy. 2008. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines 7: 889-893.
33. Rossbacher, J., and M. J. Shlomchik. 2003. The B cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance B cell immune responses in vivo. J. Exp. Med. 198: 591-602. (Pubitemid 37040393)
34. Kayaba, H., D. Dombrowicz, G. Woerly, J. P. Papin, S. Loiseau, and M. Capron. 2001. Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation. J. Immunol. 167: 995-1003. (Pubitemid 32660857)
35. Dombrowicz, D., S. Lin, V. Flamand, A. T. Brini, B. H. Koller, and J. P. Kinet. 1998. Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 8: 517-529. (Pubitemid 28196805)